Skip Navigation



Hum. Reprod. Advance Access published online on January 29, 2004
Human Reproduction, doi:10.1093/humrep/deh112
© 2004 by European Society of Human Reproduction and Embryology
This Article
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
19/3/741    most recent
deh112v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Antoine, C.
Right arrow Articles by Rozenberg, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Antoine, C.
Right arrow Articles by Rozenberg, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Received July 14, 2003
Revised October 2, 2003
Accepted November 10, 2003

Review

Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women’s Health Initiative trial

Caroline Antoine 1, Fabienne Liebens 1, Birgit Carly 1, Anne Pastijn 1, and Serge Rozenberg 1*

1 Department of Obstetrics and Gynaecology, Free Universities of Brussels (VUB-ULB) CHU Saint-Pierre, Hoogstrasse 322, 1000 Brussels, Belgium

* To whom correspondence should be addressed. E-mail: serge.rozenberg{at}skynet.be.


  Abstract

INTRODUCTION: Mortality due to breast cancer has been reported to be the same or even lower in HRT users than in non-users. This has been attributed to earlier diagnosis and to better prognosis. Nevertheless, more advanced disease in HRT users was reported recently by the Women’s Health Initiative (WHI) study. The objective of this study was to assess, using a systematic review of current literature, whether the data of the WHI study are in contradiction to observational data. METHODS: We selected 25 studies, for which we evaluated the methodology, the characteristics of the studied populations, confounding breast cancer risk factors and prognostic indicators. RESULTS: The WHI study, showing a worsening of some prognostic parameters, is in contradiction to most published observational studies. Most observational studies are retrospective, not well matched and did not consider most confounding factors. Their methodology and selection criteria varied considerably and the number of patients was often small. No differences in the distributions of histology, grade or steroid receptors were observed in the WHI trial, while this was the case in some of the observational studies. Other parameters (S phase, protein Neu, Bcl-2 gene, protein p53 and E-cadherin, cathepsin D) were not reported in the WHI trial. CONCLUSIONS: In view of these data, the current clinical message to patients should be changed: one can no longer declare that breast cancers developed while using HRT are of better prognosis.

Key words: Key words: breast cancer/HRT/prognosis/systematic review


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
T. E. Slanger, J. C. Chang-Claude, N. Obi, S. Kropp, J. Berger, E. Vettorazzi, W. Braendle, G. Bastert, S. Hentschel, and D. Flesch-Janys
Menopausal Hormone Therapy and Risk of Clinical Breast Cancer Subtypes
Cancer Epidemiol. Biomarkers Prev., April 1, 2009; 18(4): 1188 - 1196.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
L. A. Brinton, D. Richesson, M. F. Leitzmann, G. L. Gierach, A. Schatzkin, T. Mouw, A. R. Hollenbeck, and J. V. Lacey Jr.
Menopausal Hormone Therapy and Breast Cancer Risk in the NIH-AARP Diet and Health Study Cohort
Cancer Epidemiol. Biomarkers Prev., November 1, 2008; 17(11): 3150 - 3160.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. C. Barnett, M. Shah, K. Redman, D. F. Easton, B. A.J. Ponder, and P. D. P. Pharoah
Risk Factors for the Incidence of Breast Cancer: Do They Affect Survival From the Disease?
J. Clin. Oncol., July 10, 2008; 26(20): 3310 - 3316.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
P. A. Newcomb, K. M. Egan, A. Trentham-Dietz, L. Titus-Ernstoff, J. A. Baron, J. M. Hampton, M. J. Stampfer, and W. C. Willett
Prediagnostic Use of Hormone Therapy and Mortality After Breast Cancer
Cancer Epidemiol. Biomarkers Prev., April 1, 2008; 17(4): 864 - 871.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Fournier, A. Fabre, S. Mesrine, M.-C. Boutron-Ruault, F. Berrino, and F. Clavel-Chapelon
Use of Different Postmenopausal Hormone Therapies and Risk of Histology- and Hormone Receptor-Defined Invasive Breast Cancer
J. Clin. Oncol., March 10, 2008; 26(8): 1260 - 1268.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
J. A. Collins, J. M. Blake, and P. G. Crosignani
Breast cancer risk with postmenopausal hormonal treatment
Hum. Reprod. Update, November 1, 2005; 11(6): 545 - 560.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
N Angelopoulos, V Barbounis, S Livadas, D Kaltsas, and G Tolis
Effects of estrogen deprivation due to breast cancer treatment
Endocr. Relat. Cancer, September 1, 2004; 11(3): 523 - 535.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.